Merck stock after-hours at EUR 127.86: minus 0.41 percent

Merck stock was at EUR 127.86 after-hours at 9:50 p.m. CEST on October 1, 2026, down 0.41 percent versus the prior close. Merck recently announced a global license agreement for an investigational cancer drug.

Merck stock was at EUR 127.86 after-hours at 9:50 p.m. CEST on October 1, 2026, according to Lang & Schwarz. The price was down 0.41 percent versus the Lang & Schwarz prior close of EUR 128.39 on September 30, 2026.

Trading day in Germany

The Lang & Schwarz quote places Merck at EUR 127.86 after-hours, with a bid of EUR 127.76 and an ask of EUR 127.96. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Merck stock.

Merck expands oncology pipeline

On September 28, 2026, Merck & Co., Inc. announced an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D inhibitor. Under the agreement, Merck received exclusive worldwide rights to develop, manufacture and commercialize the drug. SciBrunch is entitled to an upfront payment of $400 million and potential milestone payments, giving the transaction a total potential value of $2.13 billion. Merck said the transaction had closed and would result in a $400 million pretax charge, or approximately $0.13 per share, in its third-quarter 2026 GAAP and non-GAAP results, according to Merck.

Third-quarter call scheduled

Merck said it will hold its third-quarter 2026 sales and earnings conference call at 9:00 a.m. ET on October 29, 2026. The company said executives will review the quarter’s performance, with the webcast, replay, sales and earnings release, supplemental disclosures and presentation slides to be made available through Merck, according to Business Wire.